CELL RECEPTOR DEVELOPS A FUTURE-ORIENTED THERAPY FOR HIGH MEDICAL NEEDS: CANCER AND AUTOIMMUNE DISEASES

Cell Receptor is a burgeoning Geneva-based corporation that has made groundbreaking strides in cancer treatment and autoimmune diseases with promising approaches.

Traditionally, oncology is based on the assumption that cancer cells autonomously regulate their growth. Therefore, existing treatments aim to directly kill the tumour cells while causing as minor damage as possible to other cells. Unfortunately, these methods are often associated with severe side effects that can be distressing for patients.

Cell Receptor GmbH from Kiel, Germany, has introduced a new tool in oncology that blocks cell growth and chemoresistance by targeting the critical physical interaction between growing cells and their microenvironment. No cancer cell is self-sufficient in its growth signaling. Due to this crucial fact, monoclonal antibodies directed against growth factors or their receptors are effective against cancer today. Our well-tolerated method targets growth signaling in a much broader range of action. It is effective and affordable and heralds a new era in oncology by significantly reducing the unwanted side effects of treatment and preventing treatment failure in the majority of cancer cases.

Every growing cell, including tumour cells, requires contact to platelets to divide. These platelets supply the cells with growth factors and help them escape the immune system. They also protect circulating tumour cells from shear forces. We have discovered how to block this contact to prevent the growth of tumour cells, especially metastasis and chemoresistance. Thus, we have met two critically urgent needs.

See this article: https://www.nature.com/articles/d43747-021-00133-8

#cellreceptor #cancer treatment #oncology                                    Member of